Introduction: Scalp involvement in the course of pemphigus is observed in 16-60% of patients.

Aim: To determine the prognostic significance of scalp involvement in pemphigus vulgaris and pemphigus foliaceus.

Material And Methods: A total of 75 patients (46 with pemphigus vulgaris, 29 with pemphigus foliaceus) were included into this prospective study. The following clinical data were analyzed: Pemphigus Disease Area Index, time to complete clinical remission and duration of complete clinical remission. Indirect immunofluorescence and enzyme-linked immunosorbent assay were performed to monitor serum pemphigus antibodies.

Results: Scalp involvement was observed in 30/46 (65.2%) patients with pemphigus vulgaris and 28/29 (96.6%) patients with pemphigus foliaceus. A positive correlation was found between scalp involvement and general disease severity as measured by the Pemphigus Disease Area Index ( = 0.7, < 0.05). The time required to achieve a complete clinical remission in patients with and without scalp involvement was 39.1 ±47.1 and 9.1 ±7.8 months, respectively. The duration of complete clinical remission was 14.1 ±17.4 and 105.7 ±108.8 months, respectively. The respective time required to achieve serological remission was 37.7 ±58.5 and 15.5 ±18.8 months, whereas the duration of serological remission was 9.2 ±18.8 and 39.1 ±60.1 months, respectively. The average concentration of anti-desmoglein 1 autoantibodies was significantly higher in patients with scalp involvement compared to patients without scalp involvement (109.9 ±68.0 U/ml and 21.3 ±39.4 U/ml).

Conclusions: Scalp involvement in pemphigus is associated with a higher disease severity, longer time required to achieve complete clinical and serological remission and may indicate the need for a more aggressive therapeutical approach.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041714PMC
http://dx.doi.org/10.5114/pdia.2017.71267DOI Listing

Publication Analysis

Top Keywords

scalp involvement
36
complete clinical
20
clinical remission
16
pemphigus
12
involvement pemphigus
12
pemphigus vulgaris
12
patients pemphigus
12
time required
12
required achieve
12
patients scalp
12

Similar Publications

Reactive B-cell rich lymphoid proliferation (rB-LP), once called pseudolymphoma, is a benign lymphoproliferative disorder, which is histologically characterized by dense dermal infiltrate forming reactive germinal centers with tingible body macrophages. The disease frequently involves the face, scalp, and ear lobes. Treatment includes topical or intralesional steroids, surgical resection, ultraviolet therapy, laser treatment, and radiation therapy.

View Article and Find Full Text PDF

parts of the world (1,2). CL is characterized by significant clinical variability. An ulcerated nodule on the exposed parts of the body (corresponding to the parasite inoculation site by the vector insect) is the classic presentation.

View Article and Find Full Text PDF

Background Cosmetics have become an integral part of the contemporary lifestyle. Contact dermatitis (CD) is an inflammatory skin disease resulting from exposure to an external chemical present in cosmetics. A patch test is considered the criterion standard method for detecting CD.

View Article and Find Full Text PDF

Follicular porokeratosis (FPK) is a rare subtype of porokeratosis. Follicular porokeratosis mainly occurs in men and may be localized or diffuse. Involvement of the scalp is rarely reported, and we found only one case of alopecia due to scalp FPK.

View Article and Find Full Text PDF

Background: Alopecia areata (AA) is a chronic inflammatory disease that affects the hair follicles and sometimes the nails. It usually presents as a single or multiple patches of hair loss on the scalp, but any hair-bearing skin can be involved. AA treatment depends on the severity and extent of the disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!